AG真人官方

On 7 July 2025, W. P. Carey Inc. (NYSE: WPC) entered into an underwriting agreement with Wells Fargo Securities, BofA Securities and Scotia Capital (USA) Inc. for a public offering of $400 million aggregate principal amount of 4.650% Senior Notes due 2030. The notes are expected to settle on 10 July 2025 under the company鈥檚 automatic shelf registration (File No. 333-286885).

The company will apply the net proceeds to repay a portion of borrowings outstanding under its $2.0 billion unsecured revolving credit facility and for other general corporate purposes. The underwriting agreement contains customary representations, warranties, covenants and indemnification provisions. A pricing press release was simultaneously issued (Exhibit 99.1).

• Issue Size: $400 million
• Coupon: 4.650%
• Maturity: 2030
• Expected Closing: 10 July 2025
• Use of Proceeds: Debt repayment & general corporate

No earnings figures or other financial performance data were disclosed in this Form 8-K.

Karpus Management, Inc. filed Amendment No. 2 to Schedule 13G for Eureka Acquisition Corp (EURKU) covering the event date 30 June 2025.

The registered investment adviser now reports beneficial ownership of 327,400 common shares, representing 4.28 % of the outstanding class. Karpus holds sole voting and dispositive power over the entire position and no shared power with other parties. Because the stake has fallen below the 5 % threshold, Karpus is no longer deemed a 5 % beneficial owner under Section 13(d) of the Exchange Act but remains subject to Rule 13d-1(b) reporting requirements.

The shares are held in discretionary advisory accounts managed by Karpus, which operates independently of its parent, City of London Investment Group plc, through established informational barriers. The filing affirms that the securities were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer.

Implications for investors: the reduction slightly increases EURKU鈥檚 public float and removes Karpus from the list of significant 5 % holders, potentially diminishing expectations of activist involvement. Nonetheless, a 4.28 % position remains a meaningful minority interest that could provide ongoing institutional oversight.

Ryanair Holdings plc has filed a Form 6-K to report activity under its share buy-back programme for the week of 30 June鈥�04 July 2025.

• Ordinary shares: 42,921 repurchased for cancellation at a volume-weighted average price of approximately 鈧�23.80.
• ADS-linked shares: 173,074 ordinary shares underlying American Depositary Shares acquired at an average price near US$28.9.
• These transactions form part of the buy-back scheme first announced on 20 May 2025 and will be disclosed on a weekly basis.
• All repurchased shares will be cancelled, lowering the company鈥檚 share count.
• The notice is released in line with Article 5(1)(b) of Regulation (EU) 596/2014.
• Issuer identifiers: LEI 635400BR2ROC1FVEBQ56, ISIN IE00BYTBXV33.

Cardlytics, Inc. (CDLX) 鈥� Form 144 filing indicates an insider intends to sell 5,271 common shares on or about 02-Jul-2025 through Fidelity Brokerage on Nasdaq. The proposed sale represents 鈮�0.01&苍产蝉辫;% of the company鈥檚 52.5 million shares outstanding and carries an estimated market value of $9,396.

The filer鈥攊dentified in the past-sales section as Nicholas Lynton鈥攑reviously sold 6,057 shares in two transactions during April 2025, generating gross proceeds of $10,852. The shares to be sold were acquired via restricted-stock vesting on 01-Jul-2025 and are being disposed of for personal account purposes; no cash outlay was involved in the acquisition (classified as compensation).

Because the volume is immaterial relative to the float and no undisclosed adverse information is asserted, the filing is generally routine. Nonetheless, it signals continued insider selling within a three-month window, which investors may monitor for sentiment trends rather than fundamental impact.

InnovAge Holding Corp. (INNV) filed a Form 4 disclosing that director Edward M. Kennedy Jr. received 25,316 Restricted Stock Units (RSUs) on July 1, 2025. The award was recorded at a purchase price of $0 because RSUs are equity compensation rather than open-market purchases.

The RSUs will vest in full on June 30, 2026, provided the director remains in service through that date. Upon settlement, the units will convert into an equivalent number of common shares. Following the grant, Kennedy鈥檚 direct beneficial ownership totals 68,157 shares of InnovAge common stock.

No sales, option exercises, derivative positions, or other transactions were reported. The filing therefore reflects a routine equity-compensation grant that modestly increases insider alignment but does not involve immediate cash inflows, earnings information, or strategic developments.

Form 8-K Highlights: Hyperion DeFi, Inc. (formerly Eyenovia, Inc.) filed a current report covering two principal matters: (1) departure of its Chief Operating Officer and (2) a corporate name and ticker change.

Executive departure (Item 5.02): Effective July 1, 2025, COO Bren Kern鈥檚 employment terminated in connection with a previously announced reduction-in-force. Under a Separation and Release Agreement, he will receive 12 months of base salary and up to 12 months of continued health-care benefits, conditioned upon standard release and covenant provisions. The agreement is attached as Exhibit 10.1.

Name and ticker change (Item 5.03): A Certificate of Amendment filed June 30, 2025, changed the company鈥檚 legal name from Eyenovia, Inc. to Hyperion DeFi, Inc., effective 8:00 a.m. ET on July 1, 2025. Board approval under Delaware General Corporation Law 搂242 was sufficient; no stockholder vote was required. Common shares retain the same rights and CUSIP, but the Nasdaq ticker will convert from 鈥淓YEN鈥� to 鈥淗YPD鈥� beginning July 3, 2025.

Reg FD disclosure (Item 7.01): A press release regarding the rebrand and ticker change was furnished (Exhibit 99.1) and is not deemed 鈥渇iled鈥� for Exchange Act liability.

Exhibits:

• 3.1 鈥� Certificate of Amendment (Name Change)
• 10.1 鈥� Separation and Release Agreement (COO)
• 99.1 鈥� Press Release announcing changes
• 104 鈥� Inline XBRL cover page

The filing is primarily administrative; it signals a strategic rebranding without altering share structure, while simultaneously disclosing senior management turnover that may raise continuity concerns.

Dillard鈥檚, Inc. (DDS) Form 4 filing dated 07/02/2025 discloses a modest open-market purchase by long-time insider Drue Matheny, Executive Vice President and Director. On 06/30/2025 Matheny acquired 19 Class A common shares at $413.32 each, increasing her direct holding to 403,904 shares. She also continues to hold 36,648 shares through the company retirement plan and 9,821 shares indirectly (7,300 as trustee of the GST Trust and 2,521 held by her spouse). No derivative transactions were reported.

The purchase represents less than 0.005% of her direct ownership and is immaterial to DDS鈥檚 17 million share float, yet any insider buying鈥攑articularly by a senior executive鈥攎ay be interpreted as a confidence signal. There were no sales, option exercises, or 10b5-1 plan indications, and the filing confirms her continuing status as both officer and director.

Form 4 filing overview: On 06/30/2025, MAIA Biotechnology, Inc. (ticker MAIA) granted director Cristian Luput a package of stock options under the company鈥檚 2021 Equity Incentive Plan.

• Options granted: 21,350 options to purchase common shares.
• Exercise price: $1.80 per share.
• Vesting schedule: 100% vested immediately on the grant date.
• Expiration: 06/30/2035 (10-year term).
• Post-transaction holdings: Luput now holds 21,350 derivative securities directly.

No non-derivative share transactions were reported, and the filing was made individually by the director. The grant represents routine equity compensation designed to align director incentives with shareholder value, but it modestly increases the company鈥檚 fully diluted share count.

Wintrust Financial Corp (WTFC) 鈥� Insider Form 4 Filing

Director Marla F. Glabe reported the acquisition of 428 shares of Wintrust Financial common stock on 30 June 2025 under the shareholder-approved Director鈥檚 Deferred Fee & Stock Plan. The transaction is coded 鈥淎鈥� (open-market or plan acquisition) at an indicated reference price of $112.46 per share, implying a dollar value of roughly $48,100. Following the purchase, Glabe鈥檚 direct beneficial ownership rises to 22,197 shares.

• No derivative securities were transacted.
• The filing is made by a single reporting person and bears an attorney-in-fact signature dated 2 July 2025.
• The acquisition represents about 1.9% incremental ownership relative to Glabe鈥檚 revised holdings.

While modest in size relative to WTFC鈥檚 average trading volume and market capitalization, director share accumulation can be viewed as a marginally constructive signal of insider confidence.